Investigational Drug Information for Lapachone
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Lapachone?
Lapachone is an investigational drug.
There have been 6 clinical trials for Lapachone.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 29th 2011.
The most common disease conditions in clinical trials are Neoplasms, Metabolic Syndrome X, and Metabolic Syndrome. The leading clinical trial sponsors are University of Texas Southwestern Medical Center, ArQule, and ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.).
Summary for Lapachone
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,704 |
| WIPO Patent Applications | 1,003 |
| Japanese Patent Applications | 634 |
| Clinical Trial Progress | Phase 1 (2011-12-29) |
| Vendors | 82 |
Recent Clinical Trials for Lapachone
| Title | Sponsor | Phase |
|---|---|---|
| ARQ761 + PARP Inhibitor in Refractory Solid Tumors | University of Texas Southwestern Medical Center | Phase 1 |
| ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer | University of Texas Southwestern Medical Center | Phase 1 |
| Clinical Trial of ARQ 761 in Advanced Solid Tumors | ArQule | Phase 1 |
Clinical Trial Summary for Lapachone
Top disease conditions for Lapachone
Top clinical trial sponsors for Lapachone
US Patents for Lapachone
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
